Use the Pediatric Dosing Calculator for fast, accurate dosing
The
Inside
Story
of Penny
About Penny,
DEFINITY® ambassador
Compensated by Lantheus.
Penny is a mom of three who lives in the southwestern United States. She lives with two separate heart conditions, and DEFINITY® plays a significant role in helping her healthcare team manage her care.1
The decisions you make impact real lives every day
When a suboptimal echocardiogram occurs, trust DEFINITY® to give you the inside story of your patients, like Penny.1
About Penny,
DEFINITY® ambassador
Compensated by Lantheus.
Open
Penny is a mom of three who lives in the southwestern United States. She lives with two separate heart conditions, and DEFINITY® plays a significant role in helping her healthcare team manage her care.1
Get the inside story on DEFINITY® and the impact it can have on patient and practice outcomes.
With 20+ years of clinical experience, DEFINITY® is the clear standard in ultrasound enhancing agents.1-3
Improves cardiac diagnosis and patient management4
Reduces the need for additional imaging and length of stay5
IN THE US
4 OUT OF 5
contrast-enhanced echos are
performed with DEFINITY®2
DEFINITY® IS
INCLUDED IN OVER
2400
peer-reviewed publications2
MORE THAN
21 million
studies have been performed with DEFINITY®2
DEFINITY® defined
DEFINITY® is a diagnostic ultrasound enhancing agent that uses advanced microbubble technology to opacify the left ventricular chamber and improve the delineation of the left ventricular endocardial border in patients with suboptimal echocardiograms.1,6
DEFINITY®
Unenhanced
View the latest from the DEFINITY® Educational Series
This ongoing educational series offers a range of resources, including webinars, speaker forums, and operational toolkits, designed to help you optimize your institution.
Stay updated with the latest news from DEFINITY®
Get started with ordering and reimbursement
Understanding suboptimal echo rates' impact on efficiency
UEA=ultrasound enhancing agent.
References:
-
Kurt M, Shaikh KA, Peterson L, et al. Impact of contrast echocardiography on evaluation of ventricular function and clinical management in a large prospective cohort. J Am Coll Cardiol. 2009;53(9):802-810.
-
Data on file, Lantheus.
-
Embase and Medline Search, May 2018; Data on file, Lantheus.
-
©2021 Millennium Research Group, Inc. All rights reserved. Reproduction, distribution, transmission or publication is prohibited. Reprinted with permission.
-
DEFINITY® [package insert]. N. Billerica, MA: Lantheus, Inc.
-
Sboros V, Moran CM, Pye SD, McDicken WN. Contrast agent stability: a continuous B-mode imaging approach. Ultrasound Med Biol. 2001;27(10):1367-1377.
-
Sonne C, Xie F, Lof J, et al. Differences in definity and optison microbubble destruction rates at a similar mechanical index with different real-time perfusion systems. J Am Soc Echocardiogr. 2003;16(11):1178-1185.
-
Kitzman DW, Goldman ME, Gillam LD, Cohen JL, Aurigemma GP, Gottdiener JS. Efficacy and safety of the novel ultrasound contrast agent perflutren (definity) in patients with suboptimal baseline left ventricular echocardiographic images. Am J Cardiol. 2000;86(6):669-674.
-
DEFINITY® RT [package insert]. N. Billerica, MA: Lantheus, Inc.
INDICATION
DEFINITY® is indicated, after activation, for use in adult and pediatric patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.
IMPORTANT SAFETY INFORMATION
BOXED WARNING: SERIOUS CARDIOPULMONARY REACTIONS
Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration. Most serious reactions occur within 30 minutes of administration.
- Assess all patients for the presence of any condition that precludes DEFINITY® administration.
- Always have resuscitation equipment and trained personnel readily available.
References:
- DEFINITY®. Prescribing Information. Lantheus.
- Data on file, Lantheus.
- US Food and Drug Administration. DEFINITY drug approval letter(s). Accessed June 5, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-064_Definity.cfm
- Kurt M, Shaikh KA, Peterson L, et al. Impact of contrast echocardiography on evaluation of ventricular function and clinical management in a large prospective cohort. J Am Coll Cardiol. 2009;53(9):802-810. doi:10.1016/j.jacc.2009.01.005
- Main ML, Fu JW, Gundrum J, LaPointe NA, Gillam LD, Mulvagh SL. Impact of contrast echocardiography on outcomes in critically ill patients. Am J Cardiol. 2021;150:117-122. doi:10.1016/j.amjcard.2021.03.039
- Porter TR, Mulvagh SL, Abdelmoneim SS, et al. Clinical applications of ultrasonic enhancing agents in echocardiography: 2018 American Society of Echocardiography guidelines update. J Am Soc Echocardiogr. 2018;31(3):241-274. doi:10.1016/j.echo.2017.11.013
DEFINITY® Customer Service 1.800.299.3431
BACK TO TOP